By analyzing thousands of genetic risk variants, a new algorithm developed by Columbia researchers may be able to predict your risk of developing chronic kidney disease decades before onset.
Using advanced imaging methods, researchers have gained insight into how a common target of drugs sends cellular signals, a finding that may lead to better and more precise therapeutics.
A clinical trial to test a gene therapy for some patients with dry age-related macular degeneration—a leading cause of blindness in the United States—is underway at Columbia and NewYork-Presbyterian.
Spread of a new SARS-CoV-2 variant in the New York City region that shares worrisome similarities with other recent variants has been identified by scientists at Columbia University.
Cells used to study the human blood-brain barrier in the lab aren’t what they seem, a new study has found, throwing nearly a decade’s worth of research into question.
A new study has found that up to 20% of aggressive brain cancers are fueled by overactive mitochondria and new drugs in development may be able to starve the cancers.
New images of Wnt, a signaling protein mutated in some cancers, in complex with its specific carrier, reveals atomic-level details of the molecules and a potential new drug target.
A new study conducted at Columbia and other centers found that 80% of patients with a type of slow-growing lymphoma achieved a complete remission with a single infusion of CAR T-cell immunotherapy.
In children with certain autism mutations, the diversity and severity of symptoms are often related to the identity and properties of gene units, called exons, targeted by the mutations.